An animal model of clinical kinetic analyzed to diminazene aceturate in subjects with Tripanosoma infection

  • Mochamad Lazuardi
DOI: https://doi.org/10.13181/mji.v15i2.216
Keywords: Pharmacokinetics, Chagaz, Berenil, Veriben, Tri-exponential, AIC
Abstract viewed: 539 times
PDF downloaded: 416 times

Abstract

Diminazene aceturate has been reported to inhibit the reverse transcriptase activity by intercalating action mechanism of a number of protozoon eucaryot parasitic like Trypanosoma species. The phamacokinetics of diminazene in the blood plasma of five infected goats treated with single intramuscular doses of 7 mg diminazen base kg-1 body weight was investigated. The concentrations of the drug were determined by reverse phase high performance liquid chromatography. Results show that the mean (± SD) Absorption, Distribution, Metabolism and Excretion (ADME) of the drug plasma followed a tri-exponential process with Ka (minutes-1) were obtained at 5.10-2 ± 26.10-3, α (minutes-1), K12 (minutes-1) and K21 (minutes-1) were obtained at 18.10-3 ± 1.10-2, 14.10-3 ± 1.10-2 and 1.10-3 ± 1.10-3. The mean values of β (minutes-1) and K13 (minutes-1) were obtained at 1.4.10-4 ± 4. 10-5 and 3.10-3 ± 2.10-3. The mean values of Tmax (minutes) and Cmax (µg.ml-1) were obtained at 53.71 ± 30.61 and 13.40 ± 8.13. The mean values of Vds (L), Cl (ml.minutes-1), T1/2β (hours-1) and AUC (µg.L-1.minutes) were obtained at 4.91 ± 3.12, 14.29 ± 4.08, 94.91 ± 33.23 and 12.680 ± 2.722. (Med J Indones 2006; 15:69-73)

Published
2006-05-01
How to Cite
1.
Lazuardi M. An animal model of clinical kinetic analyzed to diminazene aceturate in subjects with Tripanosoma infection. Med J Indones [Internet]. 2006May1 [cited 2023May31];15(2):69-3. Available from: https://mji.ui.ac.id/journal/index.php/mji/article/view/216
Issue
Vol 15 No 2 (2006): April-June
Section
Basic Medical Research

Copyright (c) 2006 Mochamad Lazuardi

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.